Drug Trial Radar · NCT05568797
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above
Last checked: Nov 20, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,045
Actual
Start
Oct 14, 2022
Primary completion
Feb 17, 2023
Study completion Jul 17, 2023
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to assess the immunogenicity, safety and reactogenicity of the RSV PreFusion protein 3 older adult (RSVPreF3 OA) investigational vaccine when co-administered with an adjuvanted quadrivalent influenza (FLU aQIV) vaccine, in adults aged 65 years of age (YOA).
Conditions
- Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA vaccineBiological
One dose of RSVPreF3 OA vaccine administered intramuscularly.
FLU vaccineBiological
One dose of FLU vaccine administered intramuscularly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Titers for Hemagglutination Inhibition (HI) Antibodies Against 4 FLU Vaccine Strains Expressed as Group Geometric Mean Titers (GMTs) at 1 Month After FLU Vaccine DoseTime frame: At 1 month after the FLU vaccine dose (Day 31 for both groups)
- RSV-A Neutralizing Antibody Titers Expressed as GMTsTime frame: At 1 month after the RSVPreF3 OA dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)
- RSV-B Neutralizing Antibody Titers Expressed as GMTsTime frame: At 1 month after the RSVPreF3 OA dose (Day 31 for the CoAd Group and Day 61 for the Control Group)
Locations
37 sites in 5 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Edegem, Belgium
GSK Investigational Site
Erpent, Belgium
GSK Investigational Site
Genk, Belgium
GSK Investigational Site
Ieper, Belgium
GSK Investigational Site
Espoo, Finland
GSK Investigational Site
Helsinki, Finland
GSK Investigational Site
Kokkola, Finland
GSK Investigational Site
Oulu, Finland
GSK Investigational Site
Seinäjoki, Finland
GSK Investigational Site
Tampere, Finland
GSK Investigational Site
Angers, France
GSK Investigational Site
Clermont-Ferrand, France
GSK Investigational Site
Limoges, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Montpellier, France
GSK Investigational Site
Nîmes, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Pierre-Bénite, France
GSK Investigational Site
Benalmádena, Málaga, Spain
GSK Investigational Site
Boadilla Del Monte (Madrid), Spain
GSK Investigational Site
Burgos, Spain
GSK Investigational Site
Centelles, Spain
GSK Investigational Site
La Roca Del Valles (Barcelona), Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Salamanca, Spain
GSK Investigational Site
Santander (Cantabria), Spain
GSK Investigational Site
Valladolid, Spain
GSK Investigational Site
Vic, Spain
GSK Investigational Site
Marbella - Málaga, Andalusia, Spain
GSK Investigational Site
Blackpool, United Kingdom
GSK Investigational Site
Bristol, United Kingdom
GSK Investigational Site
Chippenham, United Kingdom
GSK Investigational Site
Peterborough, United Kingdom
GSK Investigational Site
Soham, Cambridgeshire, United Kingdom
GSK Investigational Site
Bollington, Cheshire, United Kingdom
GSK Investigational Site
Chippenham, Wiltshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.